Publications by authors named "R Pontremoli"
Background: We evaluated the proportion of Type 2 diabetes (T2D) patients with chronic kidney disease (CKD) participating in the AMD (Association of Medical Diabetologists) Annals initiative who met the eligibility criteria for phase III-studies on finerenone, showing its renal and cardiovascular benefits.
Methods: This analysis involved all T2D patients seen in 2019 in 282 diabetes centers in Italy, for whom data on kidney function (estimated glomerular filtration rate and albuminuria) were available. Data are presented separately for different scenarios, covering the population with main eligibility criteria for inclusion in the FIDELIO-DKD and FIGARO-DKD trials.
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med
October 2024
Article Synopsis
- The EMPA-KIDNEY trial examined the effects of empagliflozin, an SGLT2 inhibitor, on patients with chronic kidney disease at risk for progression, assessing outcomes during and after the trial.
- A total of 6609 patients were randomized, with 4891 participating in a follow-up period after the trial where they were observed for an additional 2 years, without trial medication but allowed to use other SGLT2 inhibitors.
- Results showed that fewer primary outcome events (like kidney disease progression or cardiovascular death) occurred in the empagliflozin group (26.2%) compared to the placebo group (30.3%), suggesting lasting benefits of the drug even after the trial ended. *
Background And Hypothesis: Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout in patients with CKD.
Methods: The EMPA-KIDNEY trial randomised 6609 patients with CKD (estimated glomerular filtration rate [eGFR] ≥20 and <90 mL/min/1.
Article Synopsis
- * The study analyzed a large group of 105,163 individuals recently diagnosed with T2D to assess how prevalent rapid eGFR decline is and identified significant predictors like age, gender, and medical conditions.
- * Findings revealed that 12.9% of subjects experienced a rapid decline in eGFR, emphasizing the need to consider eGFR changes as an important factor in defining chronic kidney disease (CK
Article Synopsis
- - This study analyzed the link between metabolically healthy overweight/obese adults and major cardiovascular events (MACE) using data from 15,904 participants over 11.8 years, focusing on how LDL-cholesterol levels affect this relationship.
- - Among participants younger than 70, being overweight/obese raised the risk of MACE significantly, while older adults had a lower risk despite having high BMI.
- - Including LDL-cholesterol in the definition of healthy metabolism showed that metabolically healthy overweight/obese individuals have no increased risk of MACE compared to normal weight individuals, challenging standard assessments of health risk.